• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Record of Telephone Conversation, September 28, 2012 - Q-Pan


Submission Type: BLA    Submission ID: 125419/0    Office: OVRR

Product:
Influenza A (H5N1) Virus Monovalent Vaccine

Applicant:
ID Biomedical Corporation of Quebec

Telecon Date/Time: 28-Sep-2012 12:24 PM        Initiated by FDA? Yes

Telephone Number: 610-787-3435

Communication Categorie(s):
1. Information Request

Author: CARMEN COLLAZO-CUSTODIO

Telecon Summary:
Comments regarding the Pharmacovigilance Plan for Influenza A (H5N1) Virus Monovalent Vacine (Version 2: July 2012*) provided in the submission of July 18, 2012.

FDA Participants: CARMEN COLLAZO-CUSTODIO

Non-FDA Participants: Michael Schwartz

Telecon Body:
The following was communicated to GSK via e-mail correspondence:

 


 

______________________________________________
From:                     Collazo, Carmen 
Sent:                      Friday, September 28, 2012 12:24 PM
To:                          Michael Schwartz
Cc:                          Collazo, Carmen; Wally, Jeremy; Prutzman, Kirk C
Subject:                STN 125419-IR request PVP
Importance:        High

Dear Dr. Schwartz,

We have the following comments regarding your U.S. Pharmacovigilance Plan (PVP) for Influenza A (H5N1) Virus Monovalent Vaccine (Version 2: July 2012) provided in your July 18, 2012, submission:

1.  Sections 2.2.3.1.9 (NARCOLEPSY) and 2.3.2 (IMPORTANT POTENTIAL RISKS) of the PVP do not mention the narcolepsy cases after vaccination with Arepanrix.  Please revise these sections accordingly to include these cases.

2.  In Section 3.1.1, you stated, “Prior to an officially-declared H5N1 influenza pandemic, routine pharmacovigilance will be performed for Q-Pan H5N1 vaccine.”  Please clarify what you mean by routine pharmacovigilance in the context of a vaccine that is going to be in the Strategic National Stockpile, and will not be marketed.

Please submit your responses in an amendment to the BLA submission.

If you have any questions about this communication, please contact Carmen M. Collazo.  Thank you!

Carmen M. Collazo-Custodio, Ph.D.
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration
1451 Rockville Pike  Rm. 2236
Rockville, MD 20852

Tel. 301-796-2640
Fax: 301-827-3532
E-mail address: carmen.collazo@fda.hhs.gov